Skill Guide

Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and budget impact modeling

A suite of quantitative health economic methods used to evaluate the comparative costs and outcomes of healthcare interventions, where CEA uses clinical outcomes, CUA uses quality-adjusted life years (QALYs), and budget impact modeling (BIM) projects the financial consequences of adopting an intervention within a specific budget context.

These skills are critical for demonstrating the clinical and economic value of new therapies to payers and health systems, directly influencing reimbursement decisions, market access, and formulary placement. They transform clinical trial data into a compelling economic narrative that determines a product's commercial viability.

1 Careers

1 Categories

9.0 Avg Demand

15% Avg AI Risk

How to Learn Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and budget impact modeling

1. Master core terminology: incremental cost-effectiveness ratio (ICER), QALYs, willingness-to-pay (WTP) threshold, direct/indirect costs. 2. Understand the basic structure of a cost-effectiveness model (decision tree, Markov model) and the role of key parameters (time horizon, discounting). 3. Learn the fundamental purpose of each analysis: CEA for comparing interventions on a common clinical metric, CUA for valuing health-related quality of life, and BIM for estimating population-level financial impact.

1. Build and populate a simple Excel-based Markov model for a chronic disease, focusing on state transition probabilities and utility values. 2. Conduct a one-way sensitivity analysis to identify the most influential parameters in your model. 3. Avoid common mistakes: misaligning the time horizon with the disease, failing to discount future costs and effects, and using inappropriate comparator therapies.

1. Design and defend a complex, integrated economic model that combines CEA/CUA with a BIM to support a global value dossier. 2. Lead model validation and scenario analysis, addressing uncertainty through probabilistic sensitivity analysis (PSA) and value-of-information analysis. 3. Mentor junior analysts and communicate complex model assumptions and limitations to non-technical stakeholders, including payers and clinical key opinion leaders.

Practice Projects

Beginner

Case Study/Exercise

Constructing a Basic Cost-Effectiveness Model

Scenario

You are an analyst at a pharmaceutical company tasked with comparing a new oral medication for type 2 diabetes (Drug A) against the standard of care (Drug B). You have 1-year clinical trial data showing HbA1c reduction and hypoglycemia rates, along with unit costs for the drugs and managing complications.

How to Execute

1. Define the model structure as a simple decision tree over a 1-year time horizon. 2. Populate the model with provided clinical outcomes (e.g., probability of achieving HbA1c target on each drug) and direct medical costs (drug acquisition, monitoring, managing hypoglycemia). 3. Calculate the total cost and average effectiveness (e.g., proportion of patients at goal) for each arm. 4. Compute the incremental cost-effectiveness ratio (ICER) and interpret it against a standard WTP threshold.

Intermediate

Case Study/Exercise

Budget Impact Analysis for Formulary Submission

Scenario

A health system is considering adding a new, more expensive but more effective biologic for rheumatoid arthritis to its formulary. You must estimate the 3-year budget impact for the payer, considering expected patient uptake, displacement of existing therapies, and potential downstream savings from reduced hospitalizations.

How to Execute

1. Define the eligible population size within the payer's covered lives using epidemiology and diagnosis data. 2. Model the expected market share shift of the new biologic from existing therapies over 3 years. 3. Calculate the net budget impact by summing the drug costs for the new therapy and subtracting the costs of displaced therapies, while incorporating any offset savings from improved clinical outcomes (e.g., avoided joint surgeries). 4. Present results in a clear table showing total incremental cost per year and per member per month (PMPM).

Advanced

Case Study/Exercise

Defending a Global Value Dossier Model to a Payer Committee

Scenario

You are the lead health economist presenting the integrated CEA-CUA-BIM for a new gene therapy for a rare disease to a regional payer committee. The committee is skeptical of your high upfront drug cost, the long-term (20-year) time horizon, and the use of a novel, patient-reported utility value in your CUA.

How to Execute

1. Prepare a clear narrative that aligns the CUA (showing high QALY gain over a lifetime) with the BIM (showing a manageable annual budget impact due to small patient volume). 2. Pre-emptively address uncertainty by presenting the probabilistic sensitivity analysis (PSA) scatter plot and cost-effectiveness acceptability curve (CEAC). 3. Justify your model assumptions by referencing peer-reviewed literature, clinical expert opinion, and real-world evidence. 4. Engage in a structured dialogue to discuss risk-sharing agreements or outcomes-based contracts that could address the payer's financial uncertainty.

Tools & Frameworks

Software & Modeling Platforms

Microsoft Excel (with VBA)TreeAge ProR (BCEA, heemod packages)Python (PyMC3 for Bayesian modeling)

Excel is the industry standard for model development and transparency with payers. TreeAge is specialized software for decision analysis. R and Python are used for advanced probabilistic analysis, model validation, and automating complex sensitivity analyses.

Mental Models & Methodologies

The ISPOR Good Practices GuidelinesThe NICE Reference CaseThe Consolidated Health Economic Evaluation Reporting Standards (CHEERS)

ISPOR guidelines provide the foundational methodology for conducting and reporting economic evaluations. The NICE Reference Case is a gold-standard set of methodological requirements for cost-effectiveness submissions in the UK, often used as a benchmark. CHEERS ensures transparent and complete reporting of study results.

Interview Questions

Answer Strategy

The interviewer is testing your understanding of model architecture and your methodological rigor in handling uncertainty. Structure your answer by first outlining the model type (e.g., partitioned survival model or semi-Markov), its main health states, and key inputs. Then, specifically address survival extrapolation: you would present multiple plausible parametric distributions (exponential, Weibull, log-normal) fitted to trial data, use statistical tests (AIC/BIC) to select the best fit, and then show the impact of this choice in a scenario analysis to demonstrate robustness.

Answer Strategy

This tests your communication skills and business acumen. Acknowledge the concern and demonstrate a structured approach: 'I appreciate that feedback. Our base-case uptake was based on our launch plan. To address your concern, we can immediately look at two alternative scenarios: a conservative uptake scenario reflecting slower adoption, and a worst-case scenario based on the uptake of comparable past launches in your system. We can also discuss a phased contracting arrangement that aligns our assumptions with real-world data.'